Roche, Eli Lilly, Novo, gene therapy, Hansoh: Readout Newsletter

Wish to keep on prime of the science and politics driving biotech right this moment? Join to get our biotech e-newsletter in your inbox.

ARPA-H has unveiled a $160 million effort to hurry bespoke gene-editing therapies for uncommon illnesses into the clinic. In the meantime, Roche has deserted two Huntington’s gene-silencing medicine after disappointing knowledge, and drugmakers have stepped in to advertise Medicare’s new weight problems drug low cost program.

I acquired espresso with my cousin this morning right here in SF. Earlier than leaving for his job at an AI behemoth, he stated the bone-chilling July gloom is ideal “working climate.”